|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/29/21 Nymox Pharmaceutical Corp. 20-F 12/31/20 103:4.4M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual or Annual-Transition Report by a Foreign HTML 684K
Non-Canadian Issuer
4: EX-13.A Annual or Quarterly Report to Security Holders HTML 24K
5: EX-13.B Annual or Quarterly Report to Security Holders HTML 24K
2: EX-12.A Statement re: the Computation of Ratios HTML 28K
3: EX-12.B Statement re: the Computation of Ratios HTML 28K
12: R1 Cover HTML 59K
13: R2 Consolidated Statements of Comprehensive Loss HTML 72K
14: R3 Consolidated Statements of Financial Position HTML 83K
15: R4 Consolidated Statements of Financial Position HTML 26K
(Parenthetical)
16: R5 Consolidated Statements of Cash Flow HTML 85K
17: R6 Consolidated Statements of Changes in Equity HTML 59K
18: R7 Business Activities and Basis of Presentation HTML 30K
19: R8 Going Concern Considerations HTML 26K
20: R9 Significant Estimates HTML 25K
21: R10 Significant Accounting Policies HTML 63K
22: R11 New Accounting Standards and Interpretations HTML 28K
23: R12 Property and Equipment HTML 63K
24: R13 Intangible Assets HTML 25K
25: R14 Accounts Payable and Accrued Liabilities HTML 32K
26: R15 Operating Leases and Commitments HTML 42K
27: R16 Share Capital HTML 33K
28: R17 Stock Options HTML 47K
29: R18 Share Based Compensation HTML 30K
30: R19 Warrants HTML 43K
31: R20 Income Taxes HTML 55K
32: R21 Earnings Per Share HTML 31K
33: R22 Financial Instruments Fair Value Disclosures HTML 25K
34: R23 Finance Income and Finance Costs HTML 34K
35: R24 Segment Disclosures HTML 34K
36: R25 Concentrations HTML 29K
37: R26 Related Party Transactions HTML 34K
38: R27 Research and Development Expenses HTML 33K
39: R28 Personnel Expenses HTML 31K
40: R29 Capital Disclosures and Financial Risk HTML 25K
41: R30 Foreign Exchange Risk HTML 25K
42: R31 Credit Risk HTML 25K
43: R32 Interest Rate Risk HTML 24K
44: R33 Liquidity Risk HTML 29K
45: R34 Subsequent Events HTML 25K
46: R35 Significant Accounting Policies (Policies) HTML 92K
47: R36 Significant Accounting Policies (Tables) HTML 25K
48: R37 New Accounting Standards and Interpretations HTML 27K
(Tables)
49: R38 Property and Equipment (Tables) HTML 62K
50: R39 Accounts Payable and Accrued Liabilities (Tables) HTML 30K
51: R40 Operating Leases and Commitments (Tables) HTML 39K
52: R41 Share Capital (Tables) HTML 30K
53: R42 Stock Options (Tables) HTML 45K
54: R43 Share Based Compensation (Tables) HTML 28K
55: R44 Warrants (Tables) HTML 39K
56: R45 Income Taxes (Tables) HTML 50K
57: R46 Earnings Per Share (Tables) HTML 28K
58: R47 Finance Income and Finance Costs (Tables) HTML 32K
59: R48 Segment Disclosures (Tables) HTML 32K
60: R49 Concentrations (Tables) HTML 27K
61: R50 Related Party Transactions (Tables) HTML 28K
62: R51 Research and Development Expenses (Tables) HTML 31K
63: R52 Personnel Expenses (Tables) HTML 29K
64: R53 Liquidity Risk (Tables) HTML 27K
65: R54 Significant Accounting Policies (Details) HTML 31K
66: R55 Significant Accounting Policies (Details HTML 30K
Narrative)
67: R56 Property and Equipment (Details) HTML 48K
68: R57 Property and Equipment (Details Narrative) HTML 26K
69: R58 Intangible Assets (Details Narrative) HTML 29K
70: R59 Accounts Payable and Accrued Liabilities (Details) HTML 32K
71: R60 Operating Leases and Commitments (Details) HTML 29K
72: R61 Operating Leases and Commitments (Details 1) HTML 33K
73: R62 Operating Leases and Commitment (Details HTML 37K
Narrative)
74: R63 Share Capital (Details) HTML 26K
75: R64 Share Capital (Details Narrative) HTML 35K
76: R65 Stock Options (Details) HTML 48K
77: R66 Stock Options (Details 1) HTML 42K
78: R67 Stock Options (Details Narrative) HTML 27K
79: R68 Share Based Compensation (Details) HTML 32K
80: R69 Share Based Compensation (Details Narrative) HTML 36K
81: R70 Warrants (Details) HTML 36K
82: R71 Warrants (Details Narrative) HTML 30K
83: R72 Income Taxes (Details) HTML 37K
84: R73 Income Taxes (Details 1) HTML 27K
85: R74 Income Taxes (Details 2) HTML 79K
86: R75 Income Taxes (Details Narrative) HTML 25K
87: R76 Earnings Per Share (Details) HTML 28K
88: R77 Finance Income and Finance Costs (Details) HTML 37K
89: R78 Segment Disclosures (Details) HTML 40K
90: R79 Concentrations (Details) HTML 32K
91: R80 Related Party Transactions (Details) HTML 34K
92: R81 Related Party Transactions (Details Narrative) HTML 33K
93: R82 Research and Development Expenses (Details) HTML 37K
94: R83 Personnel Expenses (Details) HTML 31K
95: R84 Personnel Expenses (Details Narrative) HTML 29K
96: R85 Capital Disclosures and Financial Risk (Details HTML 32K
Narrative)
97: R86 Foreign Exchange Risk (Details Narrative) HTML 25K
98: R87 Credit Risk (Details Narrative) HTML 29K
99: R88 Interest Rate Risk (Details Narrative) HTML 24K
100: R89 Liquidity Risk (Details) HTML 33K
102: XML IDEA XML File -- Filing Summary XML 188K
101: EXCEL IDEA Workbook of Financial Reports XLSX 106K
6: EX-101.INS XBRL Instance -- nymox-20201231 XML 1.27M
9: EX-101.CAL XBRL Calculations -- nymox-20201231_cal XML 150K
11: EX-101.DEF XBRL Definitions -- nymox-20201231_def XML 385K
8: EX-101.LAB XBRL Labels -- nymox-20201231_lab XML 773K
10: EX-101.PRE XBRL Presentations -- nymox-20201231_pre XML 662K
7: EX-101.SCH XBRL Schema -- nymox-20201231 XSD 264K
103: ZIP XBRL Zipped Folder -- 0001640334-21-000680-xbrl Zip 122K
 | Download this zipped .zip folder |
| Files: | nymox-20201231.xml nymox-20201231.xsd nymox-20201231_cal.xml nymox-20201231_def.xml nymox-20201231_lab.xml nymox-20201231_pre.xml |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/16 Nymox Pharmaceutical Corp. 20-F 12/31/15 8:1.2M e3 Fil… Computershare/FA 6/03/11 Nymox Pharmaceutical Corp. 20-F/A 12/31/10 7:474K e3 Fil… Computershare/FA 6/30/04 Nymox Pharmaceutical Corp. 20-F 12/31/03 7:1.1M Foley & Lardner/FA 6/27/02 Nymox Pharmaceutical Corp. 20-F 12/31/01 2:246K Foley & Lardner/FA |